Alkermes (ALKS)
(Delayed Data from NSDQ)
$24.68 USD
+0.24 (0.98%)
Updated Apr 26, 2024 04:00 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALKS 24.68 +0.24(0.98%)
Will ALKS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALKS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALKS
Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
ALKS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 Release
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Other News for ALKS
Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1
Alkermes initiates Phase 2 clinical trial of ALKS 2680
First Week of June 21st Options Trading For Alkermes (ALKS)
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)